MCID: PRS123
MIFTS: 38

Persistent Generalized Lymphadenopathy

Categories: Immune diseases

Aliases & Classifications for Persistent Generalized Lymphadenopathy

MalaCards integrated aliases for Persistent Generalized Lymphadenopathy:

Name: Persistent Generalized Lymphadenopathy 12 15
Persistant Generalized Lymphadenopathy 73
Pgl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060314
UMLS 73 C0856916

Summaries for Persistent Generalized Lymphadenopathy

Disease Ontology : 12 A lymph node disease characterized by enlarged, non-painful lymph nodes occurring for more than three to six months for which no other reason can be found.

MalaCards based summary : Persistent Generalized Lymphadenopathy, also known as persistant generalized lymphadenopathy, is related to paragangliomas 1 and hereditary paraganglioma-pheochromocytoma syndromes. An important gene associated with Persistent Generalized Lymphadenopathy is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Carbon metabolism and Pyruvate metabolism and Citric Acid (TCA) cycle. The drugs Darunavir and Emtricitabine have been mentioned in the context of this disorder. Affiliated tissues include lymph node and b cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 76 Persistent generalized lymphadenopathy (PGL) is enlarged painful lymph nodes occurring in a couple of... more...

Related Diseases for Persistent Generalized Lymphadenopathy

Diseases related to Persistent Generalized Lymphadenopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 paragangliomas 1 33.0 SDHB SDHC SDHD
2 hereditary paraganglioma-pheochromocytoma syndromes 29.8 SDHA SDHAF2 SDHB SDHC SDHD TMEM127
3 paraganglioma 28.0 SDHA SDHAF2 SDHB SDHC SDHD TMEM127
4 pheochromocytoma 26.8 EPAS1 SDHA SDHAF2 SDHB SDHC SDHD
5 6-phosphogluconolactonase deficiency 10.9
6 selective igg deficiency disease 10.9 CD40LG CD79A
7 c1q nephropathy 10.9 CD40LG CD79A
8 meningovascular neurosyphilis 10.9 CD40LG CD79A
9 alpha chain disease 10.9 CD40LG CD79A
10 brill-zinsser disease 10.9 CD40LG CD79A
11 exudative glomerulonephritis 10.8 CD40LG CD79A
12 cork-handlers' disease 10.8 CD40LG CD79A
13 salpingo-oophoritis 10.8 CD40LG CD79A
14 early yaws 10.8 CD40LG CD79A
15 ventilation pneumonitis 10.8 CD40LG CD79A
16 chronic interstitial cystitis 10.8 CD40LG CD79A
17 axillary adenitis 10.8 CD40LG CD79A
18 cryofibrinogenemia 10.8 CD40LG CD79A
19 trichostrongyloidiasis 10.8 CD40LG CD79A
20 subacute bacterial endocarditis 10.8 CD40LG CD79A
21 heterophyiasis 10.8 CD40LG CD79A
22 immunoglobulin g deficiency 10.8 CD40LG CD79A
23 orbital granuloma 10.8 CD40LG CD79A
24 transient hypogammaglobulinemia of infancy 10.8 CD40LG CD79A
25 hyperglobulinemic purpura 10.8 CD40LG CD79A
26 gastroduodenitis 10.8 CD40LG CD79A
27 bacterial conjunctivitis 10.8 CD40LG CD79A
28 heavy chain disease 10.8 CD40LG CD79A
29 ophthalmia neonatorum 10.8 CD40LG CD79A
30 immunoglobulin a deficiency 1 10.8 CD40LG CD79A
31 parotid disease 10.8 CD40LG CD79A
32 cerebral arteritis 10.8 CD40LG CD79A
33 selective immunoglobulin deficiency disease 10.8 CD40LG CD79A
34 geniculate herpes zoster 10.8 CD40LG CD79A
35 erythema elevatum diutinum 10.8 CD40LG CD79A
36 sporotrichosis 10.8 CD40LG CD79A
37 fallopian tube disease 10.8 CD40LG CD79A
38 hyperimmunoglobulin syndrome 10.8 CD40LG CD79A
39 congenital syphilis 10.8 CD40LG CD79A
40 polyclonal hypergammaglobulinemia 10.8 CD40LG CD79A
41 monoclonal paraproteinemia 10.8 CD40LG CD79A
42 salpingitis 10.8 CD40LG CD79A
43 ocular toxoplasmosis 10.8 CD40LG CD79A
44 dysgammaglobulinemia 10.8 CD40LG CD79A
45 congenital hypogammaglobulinemia 10.8 CD40LG CD79A
46 acute maxillary sinusitis 10.8 CD40LG CD79A
47 chronic polyneuropathy 10.8 CD40LG CD79A
48 spinocerebellar ataxia, autosomal recessive 10 10.8 CD40LG CD79A
49 parasitic ichthyosporea infectious disease 10.8 CD40LG CD79A
50 cd40 ligand deficiency 10.8 CD40LG CD79A

Graphical network of the top 20 diseases related to Persistent Generalized Lymphadenopathy:



Diseases related to Persistent Generalized Lymphadenopathy

Symptoms & Phenotypes for Persistent Generalized Lymphadenopathy

MGI Mouse Phenotypes related to Persistent Generalized Lymphadenopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 CD40LG CD79A EPAS1 SDHB SDHC SDHD
2 homeostasis/metabolism MP:0005376 9.23 CD40LG CD79A EPAS1 SDHA SDHB SDHC

Drugs & Therapeutics for Persistent Generalized Lymphadenopathy

Drugs for Persistent Generalized Lymphadenopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Darunavir Approved Phase 4,Phase 3,Phase 2 635728-49-3, 206361-99-1 213039
2
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
3
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
4
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
5 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
11 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
12 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
13 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14
protease inhibitors Phase 4,Phase 3,Phase 2
15 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16
Tenofovir Phase 4,Phase 3,Phase 2 147127-20-6 464205
17
Abacavir Approved, Investigational Phase 3,Phase 2 136470-78-5 65140 441300
18 Dolutegravir Approved Phase 3,Phase 2 1051375-16-6 54726191
19
Efavirenz Approved, Investigational Phase 3,Phase 2 154598-52-4 64139
20 HIV Integrase Inhibitors Phase 3,Phase 2
21 Integrase Inhibitors Phase 3,Phase 2
22 Raltegravir Potassium Phase 3,Phase 2
23 Antimetabolites Phase 3,Phase 1,Not Applicable
24 Dideoxynucleosides Phase 3
25 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 3
26
Etravirine Approved Phase 2 269055-15-4 193962
27 Cytochrome P-450 CYP2C9 Inhibitors Phase 2
28 Cytochrome P-450 CYP3A Inducers Phase 2
29
Aldesleukin Approved Phase 1 85898-30-2, 110942-02-4
30
Zidovudine Approved Phase 1,Not Applicable 30516-87-1 35370
31 Analgesics Phase 1
32 Analgesics, Non-Narcotic Phase 1
33 Interleukin-2 Phase 1
34 Peripheral Nervous System Agents Phase 1
35 Anticoagulants Phase 1
36 Blood Substitutes Phase 1
37 Dextrans Phase 1
38 Plasma Substitutes Phase 1

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects Active, not recruiting NCT02770508 Phase 4 darunavir/ritonavir;Lamivudine;emtricitabine-tenofovir(FTC/TDF)
2 Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects Completed NCT01449929 Phase 3 dolutegravir 50 mg OAD;darunavir 800mg OAD;ritonavir 100mg OAD
3 Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir Completed NCT01568892 Phase 3 Dolutegravir 50 mg twice daily;Dolutegravir placebo twice daily
4 A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. Completed NCT01328041 Phase 3 dolutegravir
5 A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects Completed NCT01499199 Phase 3 Dolutegravir
6 A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Completed NCT01263015 Phase 3 Dolutegravir;Atripla;Abacavir/Lamivudine;Abacavir/Lamivudine Placebo;Dolutegravir placebo;Atripla placebo
7 A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Completed NCT01227824 Phase 3 GSK1349572 (dolutegravir);raltegravir
8 A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults Active, not recruiting NCT01231516 Phase 3 GSK1349572;Raltegravir;GSK1349572 Placebo;Raltegravir Placebo
9 Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects Terminated NCT00197145 Phase 3 GW873140
10 A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir Completed NCT00950859 Phase 2 GSK1349572 (Cohort I);GSK1349572 (Cohort II)
11 A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Completed NCT00951015 Phase 2 GSK1349572;efavirenz
12 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
13 Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy Completed NCT00000728 Phase 1 Zidovudine;Aldesleukin
14 A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes Completed NCT00001012 Phase 1 AL 721
15 A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC) Completed NCT00001009 Phase 1 Dextran sulfate
16 The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) Completed NCT00002048 Not Applicable Zidovudine

Search NIH Clinical Center for Persistent Generalized Lymphadenopathy

Genetic Tests for Persistent Generalized Lymphadenopathy

Anatomical Context for Persistent Generalized Lymphadenopathy

MalaCards organs/tissues related to Persistent Generalized Lymphadenopathy:

41
Lymph Node, B Cells

Publications for Persistent Generalized Lymphadenopathy

Articles related to Persistent Generalized Lymphadenopathy:

(show all 21)
# Title Authors Year
1
Persistent generalized lymphadenopathy (PGL) mimicking lymphoma on whole-body FDG PET/CT imaging. ( 16785807 )
2006
2
Persistent generalized lymphadenopathy and non-Hodgkin's lymphoma in AIDS: association with Rochalimaea henselae infection. ( 7496912 )
1994
3
Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome. ( 1311993 )
1992
4
An open-label, dose-ranging trial of AL 721 in patients with persistent generalized lymphadenopathy and AIDS-related complex. ( 1890604 )
1991
5
Clinical manifestations of HIV infection, including persistent generalized lymphadenopathy and AIDS-related complex. ( 2193949 )
1990
6
Lymph nodes in HIV-positive drug abusers with persistent generalized lymphadenopathy: histology, immunohistochemistry, and pathogenetic correlations. ( 2103864 )
1990
7
Immunohistopathogenesis of persistent generalized lymphadenopathy in HIV-positive patients. ( 2192430 )
1990
8
Persistent generalized lymphadenopathy (transfusion-related) in an HIV-seropositive heterosexual man with sickle-cell beta-thalassemia. ( 2209816 )
1990
9
Persistent generalized lymphadenopathy syndrome vs "AIDS"--unrelated malignant lymphoma: comparison of presenting clinical and laboratory findings in 88 patients. AIDS and Related Syndromes Study Group. ( 2773074 )
1989
10
Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. ( 2491247 )
1989
11
The value of lymph node histology in human immunodeficiency virus related persistent generalized lymphadenopathy. ( 2736139 )
1989
12
Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) antigens and genome in lymph nodes of HIV-positive patients affected by persistent generalized lymphadenopathy (PGL). ( 2556016 )
1989
13
Paracortical immunoregulatory subpopulations in lymph nodes from homosexual men with persistent generalized lymphadenopathy. ( 3284806 )
1988
14
Clinical and laboratory findings at presentation in persistent generalized lymphadenopathy vs malignant lymphoma. ( 3180127 )
1988
15
Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy. ( 2902865 )
1988
16
Elevated serum beta-2-microglobulin--a prognostic marker for development of AIDS among patients with persistent generalized lymphadenopathy. ( 3286507 )
1988
17
Abnormal antibody responses in patients with persistent generalized lymphadenopathy. ( 2966810 )
1988
18
The pre-AIDS syndromes. Asymptomatic carriers, thrombocytopenic purpura, persistent generalized lymphadenopathy, and AIDS-related complex. ( 3060521 )
1988
19
Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML). ( 3126117 )
1987
20
B-cell reactivity in homosexuals with persistent generalized lymphadenopathy (PGL). ( 3500784 )
1987
21
Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. ( 3618883 )
1987

Variations for Persistent Generalized Lymphadenopathy

Expression for Persistent Generalized Lymphadenopathy

Search GEO for disease gene expression data for Persistent Generalized Lymphadenopathy.

Pathways for Persistent Generalized Lymphadenopathy

GO Terms for Persistent Generalized Lymphadenopathy

Cellular components related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial inner membrane GO:0005743 9.46 SDHA SDHB SDHC SDHD
2 respiratory chain complex II GO:0045273 8.96 SDHB SDHC
3 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.92 SDHA SDHB SDHC SDHD

Biological processes related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.73 SDHA SDHB SDHC SDHD
2 aerobic respiration GO:0009060 9.4 SDHB SDHC
3 B cell proliferation GO:0042100 9.37 CD40LG CD79A
4 tricarboxylic acid cycle GO:0006099 9.35 SDHA SDHAF2 SDHB SDHC SDHD
5 electron transport chain GO:0022900 9.33 SDHA SDHB SDHC
6 respiratory electron transport chain GO:0022904 9.32 SDHA SDHB
7 succinate metabolic process GO:0006105 9.26 SDHA SDHB
8 mitochondrial electron transport, succinate to ubiquinone GO:0006121 8.92 SDHA SDHAF2 SDHC SDHD

Molecular functions related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 electron transfer activity GO:0009055 9.46 SDHA SDHB SDHC SDHD
2 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.32 SDHA SDHC
3 ubiquinone binding GO:0048039 9.26 SDHB SDHD
4 succinate dehydrogenase activity GO:0000104 9.13 SDHA SDHC SDHD
5 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.92 SDHA SDHB SDHC SDHD

Sources for Persistent Generalized Lymphadenopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....